SEARCH:   Advanced

Blood, 15 February 2005, Vol. 105, No. 4, pp. 1492-1499. Prepublished online as a Blood First Edition Paper on October 26, 2004; DOI 10.1182/blood-2004-06-2391. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-06-2391v1 105/4/1492    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Grüner, S. Articles by Nieswandt, B. Search for Related Content PubMed PubMed Citation Articles by Grüner, S. Articles by Nieswandt, B. Related Collections Hemostasis, Thrombosis, and Vascular Biology Cell Adhesion and Motility Signal Transduction Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice Sabine Grüner, Miroslava Prostredna, Martina Koch, Yoshiki Miura, Valerie Schulte, Stephanie M. Jung, Masaaki Moroi, and Bernhard Nieswandt From the Rudolf Virchow Center, Deutsche Forschungsgemeinschaft (DFG) Research Center for Experimental Biomedicine, University of Würzburg, Germany; and the Department of Protein Biochemistry, Institute of Life Science, Kurume University, Japan. Glycoprotein VI (GPVI) is an essential platelet collagen receptor; therefore, the inhibition of GPVI-collagen interactions may be an attractive antithrombotic strategy. We have previously shown that targeting of GPVI with antibodies leads to the depletion of the receptor and to long-term antithrombotic protection in mice. An alternative agent to interfere with GPVI-collagen interactions might be soluble GPVI acting as a competitive inhibitor, thereby averting undesired effects on platelets. To test this, we expressed soluble dimeric human GPVI, comprising the extracellular domain of the receptor fused to the human immunoglobulin Fc domain (GPVI-Fc), and compared its antithrombotic potential with that of anti-GPVI antibodies in mice. In contrast to a recent report, we found by intravital fluorescence microscopy and ultrasonic flow measurements that GPVI-Fc had no effect on platelet adhesion and thrombus formation at the injured arterial wall, whereas anti-GPVI antibodies profoundly inhibited these processes. Similar results were obtained with a fusion protein comprising the extracellular domain of mouse GPVI and human IgG-Fc. This indicates that direct targeting of GPVI provides significantly stronger protection against arterial thrombosis than soluble GPVI dimer. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. Schonberger, D. Siegel-Axel, R. Bussl, S. Richter, M. S. Judenhofer, R. Haubner, G. Reischl, K. Klingel, G. Munch, P. Seizer, et al. The immunoadhesin glycoprotein VI-Fc regulates arterial remodelling after mechanical injury in ApoE-/- mice Cardiovasc Res, July 7, 2008; (2008) cvn169v2. [Abstract] [Full Text] [PDF] C. Kleinschnitz, S. Braeuninger, M. Pham, M. Austinat, I. Nolte, T. Renne, B. Nieswandt, M. Bendszus, and G. Stoll Blocking of Platelets or Intrinsic Coagulation Pathway-Driven Thrombosis Does Not Prevent Cerebral Infarctions Induced by Photothrombosis Stroke, April 1, 2008; 39(4): 1262 - 1268. [Abstract] [Full Text] [PDF] T. Rabie, D. Varga-Szabo, M. Bender, R. Pozgaj, F. Lanza, T. Saito, S. P. Watson, and B. Nieswandt Diverging signaling events control the pathway of GPVI down-regulation in vivo Blood, July 15, 2007; 110(2): 529 - 535. [Abstract] [Full Text] [PDF] H. Li, S. Lockyer, A. Concepcion, X. Gong, H. Takizawa, M. Guertin, Y. Matsumoto, J. Kambayashi, N. N. Tandon, and Y. Liu The Fab Fragment of a Novel Anti-GPVI Monoclonal Antibody, OM4, Reduces In Vivo Thrombosis Without Bleeding Risk in Rats Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1199 - 1205. [Abstract] [Full Text] [PDF] U. J.H. Sachs and B. Nieswandt In Vivo Thrombus Formation in Murine Models Circ. Res., April 13, 2007; 100(7): 979 - 991. [Abstract] [Full Text] [PDF] K. Horii, M. L. Kahn, and A. B. Herr Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI Blood, August 1, 2006; 108(3): 936 - 942. [Abstract] [Full Text] [PDF] M. Pozgajova, U. J. H. Sachs, L. Hein, and B. Nieswandt Reduced thrombus stability in mice lacking the {alpha}2A-adrenergic receptor Blood, July 15, 2006; 108(2): 510 - 514. [Abstract] [Full Text] [PDF] P. Mangin, C. L. Yap, C. Nonne, S. A. Sturgeon, I. Goncalves, Y. Yuan, S. M. Schoenwaelder, C. E. Wright, F. Lanza, and S. P. Jackson Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcR{gamma} deficiency Blood, June 1, 2006; 107(11): 4346 - 4353. [Abstract] [Full Text] [PDF] C. Dubois, L. Panicot-Dubois, G. Merrill-Skoloff, B. Furie, and B. C. Furie Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo Blood, May 15, 2006; 107(10): 3902 - 3906. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020